Endpoints News – Biotech, drug, pharma and health news for …
WEBPfizer targeted by activist, following post-pandemic stumbles — reports. The activist investor Starboard Value has taken a stake in Pfizer, according to me ...
News – Endpoints News
WEBEnara Bio’s $32.5M Series B to support lead dark antigen program for GI cancers. 2 days ago. Financing. R&D.
About Endpoints News – Endpoints News
WEBJohn D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 20 years. Aside from ...
Endpoints at #JPM24 | Primed to unlock biopharma's next …
WEBThe Endpoints Hub will be open for coworking & networking — power up your devices, check email and grab coffee and a bite between session. On Tuesday, you’ll go to biotech downturn survival school, hear about the data private investors expect to see in a tricky capital market and find out the future plans for pharma from top execs in the ...
It’s mission critical this time as biotech looks to bounce back
WEBNow it’s time to fix that. Getting together, exploring new deals, hoping someone uncorks a whopper of a buyout, all while assessing the year ahead — these are all annual traditions set to make a comeback at the start of 2023. And this year Endpoints News will be at the heart of it all, offering a hybrid slate of events that will be both ...
Endpoints at #BIO23: The dawn of a new biotech era
WEBThe dawn of a new biotech era. The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma. Featuring conversations on dealmaking, pipeline trends, biotech funding, and more — plus a focus on what the mid-year outlook holds. Register to watch.
Big dreams dominate among next-gen biotech players
WEBSep 22, 2024 · The Endpoints 11: Big dreams dominate among next-gen biotech players | Live Event + Livestream. Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go ...
Endpoints at #JPM22 - A look at what's to come in 2022
WEBEndpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D. title sponsor.
Subscribe - Endpoints News
WEBEndpoints Weekly Recaps the most important developments Saturday at 6 AM ET (sample issue) Post-Hoc Analysis and insight from the newsroom, plus dispatches from medical meetings and conferences 1 ...
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
WEBAfter a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how the R&D landscape has shifted, new attempts to go after cancer's “undruggable” targets and how the field is thinking about where the goalposts are in what ...